Jump to content

MIN-117

Add links
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Maxim Masiutin (talk | contribs) at 07:56, 6 January 2024 (Alter: template type. Added the cs1 style template to denote Vancouver ("vanc") citation style, because references contain "vauthors" attribute to specify the list of authors.). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

MIN-117
Clinical data
Other namesWF-516
Identifiers
  • (2S)-1-[4-(3,4-Dichlorophenyl)piperidin-1-yl]-3-[2-(5-methyl-1,3,4-oxadiazol-2-yl)benzo[b]furan-4-yloxy]propan-2-ol[1]
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC25H25Cl2N3O
Molar mass454.40 g·mol−1
3D model (JSmol)
  • CC1=NN=C(O1)C2=CC3=C(O2)C=CC=C3OC[C@H](CN4CCC(CC4)C5=CC(=C(C=C5)Cl)Cl)O
  • InChI=1S/C25H25Cl2N3O4/c1-15-28-29-25(33-15)24-12-19-22(3-2-4-23(19)34-24)32-14-18(31)13-30-9-7-16(8-10-30)17-5-6-20(26)21(27)11-17/h2-6,11-12,16,18,31H,7-10,13-14H2,1H3/t18-/m0/s1
  • Key:XIYDIPLATGRHEC-SFHVURJKSA-N

MIN-117 (known formerly as WF-516) is an investigational antidepressant which is under development by Minerva Neurosciences for the clinical treatment of major depressive disorder (MDD).[2][3][4] It is described as a 5-HT1A and 5-HT2A receptor antagonist and inhibitor of serotonin and dopamine reuptake,[4][5][6] and is also reported to possess affinity for the α1A- and α1B-adrenergic receptors.[4][6] As of May 2015, MIN-117 is in phase II clinical trials for MDD.[3] In December 2019, Minerva announced that MIN-117 was no longer in clinical development for MDD after disappointing results in a phase IIb trial.[7]

See also

References

  1. ^ Saijo T, Maeda J, Okauchi T, Maeda J, Morio Y, Kuwahara Y, et al. (2012). "Presynaptic selectivity of a ligand for serotonin 1A receptors revealed by in vivo PET assays of rat brain". PLOS ONE. 7 (8): e42589. Bibcode:2012PLoSO...742589S. doi:10.1371/journal.pone.0042589. PMC 3413639. PMID 22880045.
  2. ^ "Minerva Neuroscience". Retrieved 2015-05-19.
  3. ^ a b Minerva Neurosciences (2015). "Minerva Neurosciences Reports First Quarter 2015 Financial Results and Other Key Business Updates" (Press release). GlobalNewswire. Retrieved 2015-05-19.
  4. ^ a b c Minerva Neurosciences. "Investor Presentation March 2015" (PDF). Archived from the original (PDF) on 2015-05-20. Retrieved 2015-05-19.
  5. ^ "Company Profile for Minerva Neurosciences Inc". Reuters. Archived from the original on 2015-05-20. Retrieved 2015-05-19.
  6. ^ a b Dion D (2014). "Some Nerves Surrounding Minerva Neurosciences IPO". Seeking Alpha. Retrieved 2015-05-19.{{cite web}}: CS1 maint: overridden setting (link)
  7. ^ "Minerva Neurosciences Reports Topline Results From Phase 2b Trial of MIN-117 in Major Depressive Disorder". BioSpace. Retrieved 2020-07-28.
Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=MIN-117&oldid=1193918350"